MedTrace Logo

A Trial of Tadalafil and Glycemic Traits

NCT01444651 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2017-01-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if tadalafil can help overweight and obese people metabolize blood sugar more efficiently. The investigators also want to find out if 20 mg/day of tadalafil for 3 months is safe to take without causing too many side effects. The investigators are plan to enroll 100 subjects at Massachusetts General Hospital (MGH).

Conditions

Interventions

DRUG

Tadalafil

20 mg Tadalafil taken once a day for 3 months

DRUG

Placebo

Placebo tablet taken by mouth once a day for 3 months

Sponsors & Collaborators

  • Thomas J. Wang, MD

    lead OTHER

Principal Investigators

  • Thomas J Wang, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01444651 on ClinicalTrials.gov